Press coverage about Immune Design (NASDAQ:IMDZ) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immune Design earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.7386305444454 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
IMDZ has been the subject of a number of analyst reports. Wells Fargo & Co lowered shares of Immune Design from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. Cowen restated a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. ValuEngine lowered shares of Immune Design from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Finally, Zacks Investment Research upgraded shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Monday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $13.06.
Shares of Immune Design (IMDZ) traded up $0.15 during mid-day trading on Thursday, hitting $3.75. 259,700 shares of the stock were exchanged, compared to its average volume of 545,082. Immune Design has a 52-week low of $3.50 and a 52-week high of $13.05. The company has a market capitalization of $175.41, a price-to-earnings ratio of -1.76 and a beta of 2.36.
Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.62 million. analysts forecast that Immune Design will post -1.89 earnings per share for the current fiscal year.
In related news, major shareholder Leo Guthart purchased 20,000 shares of Immune Design stock in a transaction dated Monday, January 8th. The stock was purchased at an average cost of $3.90 per share, for a total transaction of $78,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Carlos V. Paya sold 7,970 shares of Immune Design stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $4.17, for a total transaction of $33,234.90. Following the completion of the sale, the chief executive officer now owns 114,560 shares of the company’s stock, valued at $477,715.20. The disclosure for this sale can be found here. Over the last quarter, insiders bought 5,300,000 shares of company stock valued at $21,795,000 and sold 13,959 shares valued at $58,209. Insiders own 20.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/18/immune-design-imdz-receiving-somewhat-favorable-press-coverage-analysis-finds.html.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.